In vitro models to study natural killer cell dynamics in the tumor microenvironment

Front Immunol. 2023 Jun 28:14:1135148. doi: 10.3389/fimmu.2023.1135148. eCollection 2023.

Abstract

Immunotherapy is revolutionizing cancer therapy. The rapid development of new immunotherapeutic strategies to treat solid tumors is posing new challenges for preclinical research, demanding novel in vitro methods to test treatments. Such methods should meet specific requirements, such as enabling the evaluation of immune cell responses like cytotoxicity or cytokine release, and infiltration into the tumor microenvironment using cancer models representative of the original disease. They should allow high-throughput and high-content analysis, to evaluate the efficacy of treatments and understand immune-evasion processes to facilitate development of new therapeutic targets. Ideally, they should be suitable for personalized immunotherapy testing, providing information for patient stratification. Consequently, the application of in vitro 3-dimensional (3D) cell culture models, such as tumor spheroids and organoids, is rapidly expanding in the immunotherapeutic field, coupled with the development of novel imaging-based techniques and -omic analysis. In this paper, we review the recent advances in the development of in vitro 3D platforms applied to natural killer (NK) cell-based cancer immunotherapy studies, highlighting the benefits and limitations of the current methods, and discuss new concepts and future directions of the field.

Keywords: NK cells; flow cytometry; live cell imaging; microscopy; tissue sectioning; tumor microenvironment; tumor organoids; tumor spheroids.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Culture Techniques
  • Humans
  • Immunotherapy
  • Killer Cells, Natural
  • Neoplasms* / therapy
  • Tumor Microenvironment*

Grants and funding

We thank The Knut and Alice Wallenberg Foundation (Grant No 2018.0106), The Swedish Research Council (Grant No 2019-04925), The Swedish Foundation for Strategic Research (Grant No SBE13-0092), The Swedish Childhood Cancer Foundation (Grant No MT2019-0022), The Swedish Cancer Foundation (Grant No 19 0540 Pj) for financial support.